Drug
Taxotere (Docetaxel)
Taxotere (Docetaxel) is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
25%
Ph phase_1
1
25%
Ph phase_3
1
25%
Phase Distribution
1
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(2)
Detailed Status
Recruiting2
Completed2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)
Trials by Status
recruiting250%
completed250%
Recent Activity
2 active trials
Showing 4 of 4
recruiting
PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer
NCT06652607
recruitingphase_3
A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer
NCT06296706
completedphase_1
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
NCT01172028
completedphase_2
Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer
NCT00031187
Clinical Trials (4)
Showing 4 of 4 trials
NCT06652607
PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer
NCT06296706Phase 3
A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer
NCT01172028Phase 1
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
NCT00031187Phase 2
Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4